Theravance Biopharma Inc (NASDAQ:TBPHV) was downgraded by Robert W. Baird from a “neutral” rating to an “underperform” rating in a research note issued to investors on Wednesday. They presently have a $24.00 price target on the stock, up from their prior price target of $19.00. Robert W. Baird’s target price would indicate a potential upside of 23.08% from the company’s current price.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

5 Day Chart for NASDAQ:TBPHV

Receive News & Ratings for Theravance Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc and related companies with's FREE daily email newsletter.